StockNews.AI
VRTX
Forbes
201 days

FDA Approves Non-Opioid Painkiller With No Addiction Risk

1. FDA approved Vertex's non-opioid painkiller Journavx for moderate to severe pain. 2. Journavx has a list price of $15.50 per pill. 3. Analysts project $1 billion in annual sales for Journavx. 4. Vertex plans further studies for chronic pain approval. 5. Approval marks a shift towards non-addictive pain management alternatives.

+5.31%Current Return
VS
-0.53%S&P 500
$438.401/30 08:05 PM EDTEvent Start

$461.6802/02 08:11 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Very Bullish?

The approval and high sales estimates can significantly boost VRTX’s stock value, similar to previous successful drug launches.

How important is it?

Journavx’s approval presents a major growth opportunity, potentially reshaping VRTX's market positioning.

Why Long Term?

The ongoing studies and market demand for non-opioid solutions suggest sustained positive impacts on VRTX's stock over time.

Related Companies

Related News